NMN and NR for Aging Muscle: What RCTs Actually Show

NMN and NR can raise NAD+-related excitement faster than they have raised older adults' grip strength. The first meta-analysis to pool randomized trials of these NAD+ precursors found no statistically significant improvement in skeletal muscle index, handgrip strength, gait speed, or composite physical-performance measures in older adults. That does not prove the supplements cannot help. It does mean the human trial evidence does not support using them to treat or prevent sarcopenia.

The finding matters because the biological pitch sounds unusually coherent: aging lowers NAD+ availability; NAD+ supports mitochondrial function; healthier mitochondria should help muscle. In animals, NMN has improved glucose metabolism, vascular function, and muscle strength. But a plausible pathway is a hypothesis, not a clinical outcome. The missing step is whether oral NMN or NR reaches aging human skeletal muscle at an effective dose and then changes how people function.

The best pooled evidence is null on core sarcopenia outcomes

A 2025 systematic review and meta-analysis by Prokopidis et al. pooled 10 randomized controlled trials: six of NMN and four of nicotinamide riboside (NR). Participants had mean ages ranging from 60.9 to 83 years. Trials tested 250 to 2,000 mg daily for three to 24 weeks and assessed skeletal muscle index, handgrip strength, gait speed, the five-times chair stand test, or Short Physical Performance Battery scores.

Across the primary sarcopenia endpoints, the meta-analysis found no statistically significant benefit. The publication did not establish that NMN or NR improved muscle mass, grip strength, or walking speed in this population over the trial periods studied. That is the result buyers should put ahead of mechanistic diagrams and before-and-after anecdotes.

A separate 2026 systematic review and meta-analysis by Wang et al., focused on middle-aged and older people taking NMN, reached a similar conclusion: available randomized evidence did not provide definitive evidence of significant improvement in muscle function. Independent pooled reviews do not turn a null finding into proof of no effect, but they do make a confident performance claim harder to defend.

Why the biology still attracts serious interest

NAD+ is not imaginary marketing dust. It participates in cellular energy metabolism and acts as a co-substrate for sirtuins, a family of NAD+-dependent enzymes. In preclinical models, NAD+-related signaling has been linked to mitochondrial biogenesis, DNA-repair pathways, and muscle health. Aging muscle also shows NAD+ decline alongside mitochondrial dysfunction, fiber atrophy, anabolic resistance, and inflammatory signaling.

Those observations supply a reason to test NMN and NR. They do not show that swallowing either compound restores NAD+ inside skeletal muscle, activates a useful pathway there, or improves a person's ability to rise from a chair and walk safely. Animal strength gains are preclinical findings; they cannot substitute for a benefit in older humans.

The largest mechanistic problem is surprisingly basic: none of the randomized trials in the 2025 meta-analysis measured intramuscular NAD+ concentrations. Blood measures, where available in the broader field, cannot confirm target engagement inside muscle. A null functional result could mean that the pathway does not matter in human aging muscle. It could also mean that the tested supplements or doses did not deliver enough precursor to the relevant tissue. Current trials cannot separate those explanations.

There are positive signals, but they answer narrower questions

A 2024 systematic review by Wen et al. examined 10 NMN randomized trials involving 437 participants, 48.5% of them male. Five trials enrolled people older than 60. Doses ranged from 250 to 1,200 mg daily and interventions lasted six to 24 weeks. The authors could not perform a quantitative meta-analysis because the trials differed too much in populations, dosing protocols, and outcome measures.

Within that mixed evidence base, some results were statistically significant. A six-week trial in younger athletes found dose-dependent improvement in aerobic capacity at 300, 600, and 1,200 mg of NMN daily, without a strength effect. One 12-week trial using 250 mg daily reported a statistically significant interaction effect for the five-times chair stand test. Another study using 900 mg daily reported better six-minute walk distance than placebo.

These findings deserve neither dismissal nor promotion into a sarcopenia cure. The athlete study involved younger people and aerobic capacity, not older adults with sarcopenia or strength outcomes. The chair-stand and six-minute-walk results are individual outcomes from individual trials, not pooled proof that NMN improves the primary endpoints of sarcopenia. A secondary or population-specific signal can guide the next trial; it cannot settle the question.

The current trials leave too much room for a false negative

Most trials were short. The longest intervention in the pooled NMN/NR analysis lasted 24 weeks, while others lasted as little as three weeks. Sarcopenia develops over years, and meaningful changes in muscle mass and function may require sustained treatment and training. A three- to 24-week trial can test for an early effect. It cannot confidently rule out a slower one.

Dose is another unresolved issue. Many studies used 250 mg daily. The reviews raise the possibility that this may be inadequate for aging muscle, particularly because CD38, an NAD+-consuming enzyme, rises with age and inflammation. That remains a hypothesis, not an excuse to declare higher-dose NMN effective. The positive aerobic-capacity signals at 600 to 1,200 mg in younger athletes make dose-response a sensible question for future trials, but they do not establish an effective dose for older adults.

Several trials also lacked standardized diet or physical-activity control. In the Akasaka 2022 trial, participants had a mean age of 83 years, type 2 diabetes, and only seven people per group. They took 250 mg daily for 24 weeks. With so few participants and no dietary or activity controls, the study had limited ability to detect or attribute a modest functional effect. The Kim 2022 trial enrolled 26 to 27 community-dwelling adults per group, with a mean age of 72.2 years, and tested 250 mg daily for 12 weeks without dietary or physical-activity standardization.

Small, heterogeneous trials can obscure an effect, especially when a meta-analysis combines different compounds, populations, doses, and endpoints. Yet these limitations cut both ways. They also make isolated positive findings fragile. The evidence base needs better trials, not more certainty extracted from thin data.

What already has stronger practical support

For an older adult concerned about strength and function, resistance training has more direct human evidence than NAD+ precursors. A 2025 network meta-analysis of exercise interventions evaluated skeletal muscle index, handgrip strength, knee-extension strength, gait speed, chair-rise performance, and Timed Up and Go. Exercise remains the primary intervention tested for age-related sarcopenia.

Nutrition can add to that foundation in some settings. A 2023 meta-analysis of whey protein during resistance training included seven randomized trials with 591 adults aged 60 or older who had sarcopenia. A 2026 review of amino acid supplementation plus resistance training included nine randomized trials and 496 participants with sarcopenia; it reported improved handgrip strength (standardized mean difference 0.69, 95% confidence interval 0.04 to 1.35) and gait speed, although the authors rated the evidence low to very low certainty.

HMB has also produced more directly relevant signals when paired with training. In a 2024 randomized, double-blind trial, older post-acute-care patients with sarcopenia received 3 g per day of calcium HMB or placebo while both groups completed 12 weeks of resistance training. The intervention was designed to assess handgrip strength, Short Physical Performance Battery performance, and four-meter gait speed. These results do not make HMB universally appropriate, but they illustrate what the NMN/NR trials often lacked: a defined training background and sarcopenia-focused outcomes.

What would change the NMN or NR verdict?

A useful next-generation trial would enroll older adults with confirmed low baseline muscle NAD+ status; compare a sufficiently justified dose against placebo; run for at least six months; and give both groups structured resistance training. It should measure intramuscular NAD+ to show whether the supplement reaches its intended tissue, then test prespecified sarcopenia outcomes such as skeletal muscle index, handgrip strength, and gait speed. Muscle-biopsy measures of mitochondrial respiratory capacity could connect target engagement to function, though they would still be mechanistic endpoints rather than patient outcomes.

NR also has reported adverse effects in the 2024 review, including thrombocytopenia, diarrhea, nausea, skin rash, flushing, and leg cramps. The available evidence does not establish whether these effects differ from NMN because of tissue delivery, metabolism, dose, or study design. Anyone considering either supplement should discuss medication interactions and individual risks with a clinician rather than treating "NAD+ support" as a safety label.

NMN and NR have a credible biological rationale, but randomized trials in older adults have not shown statistically significant improvement in skeletal muscle index, handgrip strength, or gait speed at 250 to 2,000 mg daily over three to 24 weeks.

The practical verdict is straightforward. NMN and NR remain experimental options for aging muscle, not evidence-based sarcopenia treatments. Spend effort first on progressive resistance training, adequate nutrition, and a clinical evaluation when weakness, falls, or unintentional weight loss appear. The NAD+ hypothesis needs trials that prove delivery to muscle and improvement in outcomes people can feel.